Myomo R&D Spending Growth & History (MYO)
Myomo's r&d spending was $6.9M for fiscal 2025.
View full Myomo company overviewMyomo annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.9M | $2.2M | +45.51% |
| 2024 | 2024-12-31 | $4.8M | $2.1M | +81.00% |
| 2023 | 2023-12-31 | $2.6M | $153,998 | +6.20% |
| 2022 | 2022-12-31 | $2.5M | −$74,878 | −2.93% |
| 2021 | 2021-12-31 | $2.6M | $888,179 | +53.21% |
| 2020 | 2020-12-31 | $1.7M | −$80,321 | −4.59% |
| 2019 | 2019-12-31 | $1.7M | −$89,124 | −4.85% |
| 2018 | 2018-12-31 | $1.8M | $86,902 | +4.96% |
| 2017 | 2017-12-31 | $1.8M | $630,780 | +56.27% |
| 2016 | 2016-12-31 | $1.1M | — | — |
Myomo quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.7M | −$280,868 | −14.03% |
| Q1 2026 | 2026-03-31 | $1.6M | −$166,864 | −9.32% |
| Q4 2025 | 2025-12-31 | $1.6M | $65,119 | +4.18% |
| Q3 2025 | 2025-09-30 | $1.5M | $278,790 | +22.32% |
| Q2 2025 | 2025-06-30 | $2.0M | $994,107 | +98.70% |
| Q1 2025 | 2025-03-31 | $1.8M | $833,809 | +87.20% |
| Q4 2024 | 2024-12-31 | $1.6M | $681,699 | +77.64% |
| Q3 2024 | 2024-09-30 | $1.2M | $531,614 | +74.12% |
| Q2 2024 | 2024-06-30 | $1.0M | $442,989 | +78.51% |
| Q1 2024 | 2024-03-31 | $956,215 | $479,224 | +100.47% |
| Q4 2023 | 2023-12-31 | $878,005 | — | — |
| Q3 2023 | 2023-09-30 | $717,256 | $26,849 | +3.89% |
| Q2 2023 | 2023-06-30 | $564,235 | −$68,637 | −10.85% |
| Q1 2023 | 2023-03-31 | $476,991 | −$182,545 | −27.68% |
| Q3 2022 · Sep 30 | 2022-09-30 | $690,407 | $49,179 | +7.67% |
| Q2 2022 | 2022-06-30 | $632,872 | $32,756 | +5.46% |
| Q1 2022 | 2022-03-31 | $659,536 | $133,569 | +25.39% |
| Q4 2021 | 2021-12-31 | $790,056 | $371,298 | +88.67% |
| Q3 2021 | 2021-09-30 | $641,228 | $295,562 | +85.51% |
| Q2 2021 | 2021-06-30 | $600,116 | $202,305 | +50.85% |
| Q1 2021 | 2021-03-31 | $525,967 | $19,014 | +3.75% |
| Q4 2020 | 2020-12-31 | $418,758 | −$23,765 | −5.37% |
| Q3 2020 | 2020-09-30 | $345,666 | −$87,399 | −20.18% |
| Q2 2020 | 2020-06-30 | $397,811 | −$29,762 | −6.96% |
| Q1 2020 | 2020-03-31 | $506,953 | $60,605 | +13.58% |
| Q4 2019 | 2019-12-31 | $442,523 | −$87,096 | −16.45% |
| Q3 2019 | 2019-09-30 | $433,065 | −$16,608 | −3.69% |
| Q2 2019 | 2019-06-30 | $427,573 | −$59,409 | −12.20% |
| Q1 2019 | 2019-03-31 | $446,348 | $73,989 | +19.87% |
| Q4 2018 | 2018-12-31 | $529,619 | $172,752 | +48.41% |
| Q3 2018 | 2018-09-30 | $449,673 | $120,316 | +36.53% |
| Q2 2018 | 2018-06-30 | $486,982 | −$221,640 | −31.28% |
| Q1 2018 | 2018-03-31 | $372,359 | $15,474 | +4.34% |
| Q4 2017 | 2017-12-31 | $356,867 | — | — |
| Q3 2017 | 2017-09-30 | $329,357 | $91,669 | +38.57% |
| Q2 2017 | 2017-06-30 | $708,622 | $450,340 | +174.36% |
| Q1 2017 | 2017-03-31 | $356,885 | — | — |
| Q3 2016 | 2016-09-30 | $237,688 | — | — |
| Q2 2016 | 2016-06-30 | $258,282 | — | — |
Myomo r&d spending trends
Over the last five fiscal years, Myomo's r&d spending increased from $1.7M to $6.9M, a change of $5.3M. The latest reported quarter, Q2 2026, shows $1.7M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Myomo source filings ↗